STOCK TITAN

Danaher Corp. - DHR STOCK NEWS

Welcome to our dedicated news page for Danaher (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Danaher's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Danaher's position in the market.

Rhea-AI Summary
Danaher (DHR) reported first quarter 2024 results with net earnings of $1.1 billion, $1.45 per diluted common share, and non-GAAP adjusted diluted net earnings per common share at $1.92. Revenues decreased 2.5% year-over-year to $5.8 billion, with non-GAAP core revenue down by 4.0%. Operating cash flow was $1.7 billion and non-GAAP free cash flow at $1.4 billion. Despite revenue decline, President and CEO Rainer M. Blair expressed satisfaction with the performance, highlighting improvements in the bioprocessing and molecular diagnostics businesses. The outlook for the second quarter 2024 anticipates a mid-single-digit decrease in non-GAAP core revenue, while the full year 2024 expects a low-single-digit decline. Danaher will discuss these results and guidance in a webcast and conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.21%
Tags
-
Rhea-AI Summary
Danaher (NYSE: DHR) will webcast its quarterly earnings conference call for the first quarter 2024 on April 23, 2024, discussing financial performance and future expectations. The call will be available on Danaher's website with a replay option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
-
Rhea-AI Summary
Danaher Corporation (NYSE: DHR) CEO Rainer M. Blair to present at TD Cowen Healthcare Conference. Webcast available on danaher.com.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
conferences
Rhea-AI Summary
Danaher Corporation (NYSE: DHR) commits to science-based greenhouse gas emission reduction targets, aiming for net-zero value chain emissions by 2050. The company plans to reduce Scope 1 and 2 GHG emissions by 50.4% by 2032 compared to 2021, aligning with the Science Based Targets initiative (SBTi).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
none
-
News
Rhea-AI Summary
Danaher Corporation (DHR) declares a quarterly cash dividend of $0.27 per share, strengthening investor confidence.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
dividends
-
Rhea-AI Summary
Danaher Corporation (NYSE: DHR) has launched a strategic collaboration with Cincinnati Children's Hospital Medical Center to improve patient safety by addressing a leading cause of failure in clinical trials. The program aims to improve liver organoid technology for drug toxicity screening, expand genetic diversity of screening, and accelerate therapy development. More than 20% of clinical trials fail due to drug-induced liver injury, causing as much as $3 billion annually in lost effort. The collaboration will be led by Molecular Devices, a Danaher subsidiary, and will focus on developing more streamlined, scalable, and genetically diverse liver organoid technology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.21%
Tags
none
Rhea-AI Summary
Danaher Corporation (NYSE: DHR) announced results for Q4 and full year 2023, with net earnings of $1.1 billion and $4.2 billion respectively. Revenues decreased 10.0% and 10.5% year-over-year for Q4 and full year 2023. Operating cash flow was $1.6 billion for Q4 and $6.5 billion for the full year. The company anticipates non-GAAP core revenue to be down high-single digits for Q1 2024 and low-single digits for the full year 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
-
Rhea-AI Summary
Danaher Corporation (NYSE: DHR) and the Innovative Genomics Institute (IGI) have launched a collaborative center to develop gene-editing therapies for rare and other diseases. The center, known as the Danaher-IGI Beacon for CRISPR Cures, aims to use CRISPR-based gene editing to address hundreds of diseases with a unified research, development, and regulatory approach.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
none
-
Rhea-AI Summary
Danaher Corporation (DHR) anticipates a decrease in estimated revenues in the low-double digit percent range year-over-year for the fourth quarter of 2023. Estimated non-GAAP core revenue is expected to decline in the low-double digit percent range, above the previously announced guidance of a high-teens percent decline. Estimated non-GAAP base business core revenue is expected to decline in the mid-single digit percent range, in line with the previously announced guidance. President and CEO, Rainer M. Blair, will provide further details at the J.P. Morgan Healthcare Conference and the quarterly earnings conference call on January 30, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
none
Rhea-AI Summary
Danaher Corporation (NYSE: DHR) President and CEO Rainer M. Blair to present at J.P. Morgan Healthcare Conference on January 9, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
conferences
Danaher Corp.

NYSE:DHR

DHR Rankings

DHR Stock Data

177.69B
659.36M
10.76%
81.69%
0.86%
Instruments and Related Products Manufacturing for Measuring, Displaying, and Controlling Industrial Process Variables
Manufacturing
Link
US
Washington

About DHR

Danaher Corporation is an American globally diversified conglomerate founded by brothers Stephen and Mitchell Rales in 1984. Headquartered in Washington, D.C., the company designs, manufactures, and markets medical, industrial, and commercial products and services.